Yet, 2-year DFS in both studies was similar, except among patients with stage IIIA (control group in ADAURA vs our EGFR-positive NSCLC group: stage IB: 71% vs 78%; stage II: 56% vs 57%; stage IIIA: 32% vs 47%), which suggests the limited impact of adjuvant chemotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.